Protara Therapeutics, Inc.

Stage 4 · Declining · week 21

As of Oct 22, 2026, Protara Therapeutics is in Stage 4, the downtrend phase, now in week 21 (since May 26, 2026). It closed at $2.44, 67.7% below its 52-week high and below its 200-day average, which is falling.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. More about the company

$2.44

-4.31% today

$144M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TARA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S4 15w

S3 14w

S2 24w

S4 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 20w → S1 6w → S2 11w → S3 12w → S4 15w → S1 5w → S2 12w → S3 14w → S4 13w → S1 5w → S2 24w → S3 7w → S4 21w current

Total tracked: 165 weeks across 13 stage runs.

TARA among Biotechnology373rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…373	TARAProtara Therapeutics, Inc.	Stage 4 · wk 21	21	−31.1%

vs 52W High

-67.7%

$2.32 lo$7.56 hi

67.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 21

1w13w26w

Week 21, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-47.6%

200 DMA: $4.65 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.70x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-31.1%

-39.3%

-53.6%

YTD

-54.6%

-54.8%

Scan Membership

Breakout Watch

Latest: 2024-12-12

6 appearances in last 60 days. First seen: 2019-02-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 21 · Vol 1.70x

2026-10-21S4

Wk 21 · Vol 0.88x

2026-10-20S4

Wk 21 · Vol 1.49x

2026-10-19S4

Wk 21 · Vol 1.19x

2026-10-16S4

Wk 21 · Vol 1.19x

2026-10-15S4

Wk 20 · Vol 0.89x

2026-10-14S4

Wk 20 · Vol 0.73x

2026-10-13S4

Wk 20 · Vol 0.98x

2026-10-12S4

Wk 20 · Vol 1.16x

2026-10-09S4

Wk 20 · Vol 1.13x

2026-10-08S4

Wk 19 · Vol 1.34x

2026-10-07S4

Wk 19 · Vol 0.82x

Moving averages & range

50 DMA

$3.37

200 DMA

$4.65

52W High

$7.56

52W Low

$2.32

5D Low

$2.32

Resistance levels (recent highs)

20d High

$3.28

60d High

$4.12

120d High

$5.66

250d High

$7.56

Next resistance

+34.4%

to 20d High

ROE

-45.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Protara Therapeutics: quick answers

What stage is Protara Therapeutics in?

As of Oct 22, 2026, Protara Therapeutics (TARA) is in Stage 4, the downtrend phase. It entered Stage 4 on May 26, 2026 and is in week 21. What the four stages mean

Is Protara Therapeutics in an uptrend?

No. Protara Therapeutics is in a Stage 4 downtrend. It trades 47.6% below its 200-day average, which is falling.

How far is Protara Therapeutics from its 52-week high?

Protara Therapeutics closed at $2.44 on Oct 22, 2026, 67.7% below its 52-week high of $7.56. Its 52-week low is $2.32.

How has Protara Therapeutics performed over the past year?

As of Oct 22, 2026, Protara Therapeutics is down 54.8% over the past year and down 54.6% so far in 2026.

Which sector and industry is Protara Therapeutics in?

Protara Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.